[go: up one dir, main page]

PE20010708A1 - Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba - Google Patents

Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba

Info

Publication number
PE20010708A1
PE20010708A1 PE2000001069A PE0010692000A PE20010708A1 PE 20010708 A1 PE20010708 A1 PE 20010708A1 PE 2000001069 A PE2000001069 A PE 2000001069A PE 0010692000 A PE0010692000 A PE 0010692000A PE 20010708 A1 PE20010708 A1 PE 20010708A1
Authority
PE
Peru
Prior art keywords
antagonist
structural analog
receiver
gaba
synthetic combinations
Prior art date
Application number
PE2000001069A
Other languages
English (en)
Inventor
Lakhbir Singh
John Huges
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20010708A1 publication Critical patent/PE20010708A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE AL USO DE UNA COMBINACION SINERGICA QUE COMPRENDE a)UN ANTAGONISTA DEL RECEPTOR DE NEUROCININA 1 (NK1) DE PREFERENCIA BENZOFURAN-2-ILMETIL ESTER DEL ACIDO [2-(1H-INDOL-3-IL)-1-METIL-1-(1-FENIL-ETILCARBAMOIL)-ETIL]CARBAMICO [R-(R*,S*)] Y b)UN ANALOGO DE GABA COMO GABAPENTINA, PREGABALINA; SIENDO LA PROPORCION DEL ANALOGO DE GABA Y EL ANTAGONISTA DEL RECEPTOR DE NK1 DE 50:1 A 1:1. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICO, DIABETICO, POST QUIRURUGICO, POST TRAUMATICO, NEURALGIA POSTHEPATICA, NEUROPATIA PERIFERICA, INFECCION CON HIV, ESCLEROSIS MULTIPLE, HIPOTIROIDISMO, QUIMIOTERAPIA CONTRA EL CANCER
PE2000001069A 1999-10-07 2000-10-06 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba PE20010708A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
PE20010708A1 true PE20010708A1 (es) 2001-07-27

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001069A PE20010708A1 (es) 1999-10-07 2000-10-06 Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba

Country Status (38)

Country Link
EP (2) EP1221950B1 (es)
JP (2) JP2003510356A (es)
KR (1) KR20020060192A (es)
CN (1) CN1387434A (es)
AP (1) AP2002002501A0 (es)
AR (1) AR029646A1 (es)
AT (1) ATE269072T1 (es)
AU (2) AU7663300A (es)
BG (1) BG106548A (es)
BR (1) BR0014598A (es)
CA (1) CA2385930A1 (es)
CO (1) CO5280195A1 (es)
CR (1) CR6614A (es)
CZ (1) CZ20021116A3 (es)
DE (1) DE60011650T2 (es)
DK (1) DK1221950T3 (es)
EA (1) EA004266B1 (es)
EE (1) EE200200185A (es)
ES (1) ES2220542T3 (es)
GT (1) GT200000166A (es)
HR (1) HRP20020286A2 (es)
HU (1) HUP0203466A3 (es)
IL (1) IL148965A0 (es)
IS (1) IS6318A (es)
MA (1) MA26826A1 (es)
MX (1) MXPA02003484A (es)
NO (1) NO20021625L (es)
NZ (1) NZ517949A (es)
OA (1) OA12063A (es)
PA (1) PA8504301A1 (es)
PE (1) PE20010708A1 (es)
PL (1) PL357498A1 (es)
PT (1) PT1221950E (es)
SK (1) SK4542002A3 (es)
TR (1) TR200200913T2 (es)
UY (1) UY26376A1 (es)
WO (2) WO2001024792A1 (es)
ZA (1) ZA200202675B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
EP1558218A1 (en) * 2002-10-08 2005-08-03 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
RU2544552C2 (ru) 2010-07-30 2015-03-20 Торэй Индастриз, Инк. Терапевтическое средство или профилактическое средство для нейропатической боли
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
US20220175707A1 (en) * 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
WO1998024439A1 (en) * 1996-12-02 1998-06-11 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
CN1387434A (zh) 2002-12-25
PA8504301A1 (es) 2002-08-26
EP1221950A1 (en) 2002-07-17
NO20021625D0 (no) 2002-04-05
CR6614A (es) 2003-12-04
SK4542002A3 (en) 2003-09-11
CA2385930A1 (en) 2001-04-12
WO2001024792A9 (en) 2002-09-06
EE200200185A (et) 2003-04-15
DE60011650D1 (de) 2004-07-22
AR029646A1 (es) 2003-07-10
GT200000166A (es) 2002-03-30
CO5280195A1 (es) 2003-05-30
CZ20021116A3 (cs) 2003-05-14
EA200200303A1 (ru) 2002-08-29
WO2001024791A1 (en) 2001-04-12
ES2220542T3 (es) 2004-12-16
EA004266B1 (ru) 2004-02-26
AU1696201A (en) 2001-05-10
EP1233766A1 (en) 2002-08-28
NZ517949A (en) 2003-08-29
BG106548A (en) 2002-12-29
MXPA02003484A (es) 2004-09-10
EP1221950B1 (en) 2004-06-16
JP2003510355A (ja) 2003-03-18
KR20020060192A (ko) 2002-07-16
TR200200913T2 (tr) 2002-09-23
PL357498A1 (en) 2004-07-26
WO2001024792A1 (en) 2001-04-12
DK1221950T3 (da) 2004-09-20
UY26376A1 (es) 2000-12-29
BR0014598A (pt) 2002-06-11
NO20021625L (no) 2002-04-05
DE60011650T2 (de) 2005-07-14
OA12063A (en) 2006-05-03
MA26826A1 (fr) 2004-12-20
PT1221950E (pt) 2004-08-31
AU7663300A (en) 2001-05-10
HUP0203466A3 (en) 2005-03-29
IL148965A0 (en) 2002-11-10
AP2002002501A0 (en) 2002-06-30
JP2003510356A (ja) 2003-03-18
IS6318A (is) 2002-03-21
HUP0203466A2 (hu) 2003-02-28
HRP20020286A2 (en) 2003-08-31
ZA200202675B (en) 2003-04-15
ATE269072T1 (de) 2004-07-15

Similar Documents

Publication Publication Date Title
PE20010708A1 (es) Combinaciones sinteticas de un antagonista de receptor de nk1 y un analogo estructural de gaba
RU2008111710A (ru) Композиция для чрескожной доставки лекарственного средства
MX9801111A (es) Tableta moldeada masticable que contiene sustancias medicinalmente activas.
BR0313343A (pt) Uso de uma mistura de agentes permeantes, soluções para aplicação ungueal e periungueal e uso de uma solução para aplicação ungueal e periungueal
CA2344318A1 (en) Methods for administration of antibiotics
MY115385A (en) Parasiticide formulations suitable for dermal application
IE940583L (en) Topical antimicrobial pharmaceutical compositions
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
MY100947A (en) External pharmaceutical composition.
AU9021298A (en) Agmatine as a treatment for neuropathic pain
CA2383222A1 (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
IL135306A (en) Transdermal therapeutic system (tts) for the administration of oxybutynin
EP2314627A3 (en) Method for the treatment of multiple sclerosis
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
NZ301153A (en) Transdermal delivery of acid-labile drugs; compositions and methods
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
WO1999027990A3 (en) Stereospecific delivery of a drug using electrotransport
NO20024796D0 (no) Preparat for anvendelse som penetrasjonsfremmer i transdermale formuleringer for meget lipofilt aktive ingredienser
CA2282840A1 (en) S-2'-(2-(1-methyl-2-piperidyl) ethyl) cinnamanilide as a 5-ht2 receptor antagonist
PE56194A1 (es) Composicion analgesica
HRP20110038T1 (hr) Metoda liječenja dijabetesa tipa-2
EA200200211A1 (ru) Фармацевтическая композиция и ее приготовление
RU93048128A (ru) Стимулирование роста свиней
ZA973749B (en) Transdermal administration of steroid hormones using diethanolamides of C12-C18 fatty acids as permeation enhancers.
AU1783699A (en) Compositions for the transdermal and dermal administration of biologically active agents

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed